We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

64 hedge funds and large institutions have $244M invested in Cymabay Therapeutics in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more capital invested

Capital invested by funds: $65M → $244M (+$179M)

267% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 6

250% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 10

219% more call options, than puts

Call options by funds: $402K | Put options by funds: $126K

64% more funds holding

Funds holding: 39 → 64 (+25)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
64
Holders Change
+25
Holders Change %
+64.1%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
35
Increased
22
Reduced
6
Closed
10
Calls
$402K
Puts
$126K
Net Calls
+$276K
Net Calls Change
+$247K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$15.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.7M
3
BBA
Baker Bros. Advisors
New York
+$11.5M
4
RG
Redmile Group
California
+$11.1M
5
Franklin Resources
Franklin Resources
California
+$10.1M

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$3.74M
2
JGC
J. Goldman & Co
New York
-$1.73M
3
A
Abingworth
United Kingdom
-$387K
4
MWNA
Marshall Wace North America
New York
-$242K
5
ACI
Alpha Cubed Investments
California
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Credit Suisse
Switzerland
$127K +$107K +15,842 New
SPC
52
Sigma Planning Corp
Michigan
$121K +$6.76K +1,000 +7%
NC
53
Nexthera Capital
New York
$121K +$101K +15,000 New
Two Sigma Advisers
54
Two Sigma Advisers
New York
$111K +$93.3K +13,800 New
Barclays
55
Barclays
United Kingdom
$107K -$10.2K -1,509 -10%
PCM
56
Prelude Capital Management
New York
$57K +$48K +7,100 New
IA
57
IFP Advisors
Florida
$40K +$6.76K +1,000 +25%
TRCT
58
Tower Research Capital (TRC)
New York
$39K +$33.1K +4,898 New
UBS Group
59
UBS Group
Switzerland
$24K -$11.8K -1,738 -37%
LTFS
60
Ladenburg Thalmann Financial Services
Florida
$14K -$31.8K -4,700 -73%
Parallax Volatility Advisers
61
Parallax Volatility Advisers
California
$12K +$10.1K +1,500 New
Wells Fargo
62
Wells Fargo
California
$4K +$3.38K +500 New
AIS
63
Accurate Investment Solutions
Pennsylvania
$2K +$2.03K +300 New
GTC
64
Ghost Tree Capital
New York
– -$3.74M -650,000 Closed
TC
65
TFS Capital
Pennsylvania
– -$250K -43,365 Closed
MWNA
66
Marshall Wace North America
New York
– -$242K -40,416 Closed
ACI
67
Alpha Cubed Investments
California
– -$115K -20,000 Closed
Group One Trading
68
Group One Trading
Illinois
– -$27.8K -4,108 Closed
Federated Hermes
69
Federated Hermes
Pennsylvania
– -$14K -2,393 Closed
AIM
70
Acrospire Investment Management
Illinois
– -$11K -1,876 Closed
SSB
71
Sandy Spring Bank
Maryland
– -$8K -1,325 Closed
PA
72
Parallel Advisors
California
– -$3K -400 Closed
Manulife (Manufacturers Life Insurance)
73
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1K -257 Closed
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
– +$34 +5 New
1 2
3

CBAY Hedge Fund Activity: Q3 2017 in Review

64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2017, worth a combined $244M — up 275% from $65M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new CBAY positions and 10 closed out — a net gain of 25 holders — while 22 added to existing stakes and 6 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $15.9M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.74M sold.

  • 64 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2017, up from 39 in Q2 2017.
  • Funds reported $244M of Cymabay Therapeutics stock for Q3 2017, up 275% quarter-over-quarter.
  • 35 funds opened new Cymabay Therapeutics positions in Q3 2017 and 10 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $15.9M added.
  • The largest Cymabay Therapeutics seller in Q3 2017 was Ghost Tree Capital, an estimated $3.74M sold.

Based on aggregated 13F filings for Q3 2017.